Written by the Nuvirox Research Team
Short answer: a small 2026 pilot trial found that a week of NRPT (NAD+ precursor plus pterostilbene) significantly reduced hot flashes, bloating, and poor sleep in women in the menopause transition. It's a genuinely promising, very recent result — and also a small, open-label pilot that needs replication before it's conclusive.
Key Points
- NAD+ is required as a cofactor for the enzymes that convert estrone (E1) to estradiol (E2), the more active estrogen — and both estradiol and NAD+ decline with age.
- A 2026 open-label pilot trial found 7 days of NRPT reduced the frequency and severity of hot flashes, bloating, and poor sleep in women with menopausal symptoms.
- The trial was small, short (1 week), and open-label (not placebo-controlled) — real limitations that call for a larger, blinded follow-up.
The estrogen-NAD+ connection
Here's the mechanistic hook that makes this more than a coincidental association: the reduced form of NAD+ (NADPH) is the redox cofactor required by the dehydrogenase enzymes that convert estrone (E1) into estradiol (E2) — the more biologically active form of estrogen that declines sharply during the menopause transition. Since NAD+ availability itself also declines with age, researchers have hypothesized that restoring NAD+ levels might support this conversion pathway and, in turn, ease some symptoms tied to falling estradiol.
What the new pilot trial actually found
A 2026 open-label pilot trial tested this directly: women were given NRPT (a combination of nicotinamide riboside and the polyphenol pterostilbene, at the standard 250 mg NR / 50 mg PT dose) for 7 days, and outcomes were compared between women in the menopause transition and those who weren't. In the menopausal-symptoms group, the trial found significant decreases in both the frequency and severity of bloating, hot flashes, and poor sleep compared to baseline, accompanied by a significant increase in the E2/E1 ratio — consistent with the proposed mechanism actually shifting in the expected direction [1]. The group without menopausal symptoms didn't show these same changes, which is a reassuring sign that the effect tracked with the biology it was supposed to.
Study snapshot: 2026 NRPT menopause pilot trial
| Design | Open-label, pilot, two-arm parallel-group |
| Population | Women with vs. without menopausal symptoms |
| Dose / duration | 250 mg NR + 50 mg pterostilbene/day, 7 days |
| Key finding | Reduced hot flash frequency/severity, bloating, poor sleep; E2/E1 ratio increased |
The honest limitations
This is a real and recent finding, but it's important to be precise about what kind of trial it is. It was open-label — meaning participants and researchers knew who was getting the supplement, with no placebo group for comparison — which makes it more susceptible to placebo effects and expectation bias, both of which are well-documented in hot-flash research specifically (placebo response rates in menopause symptom trials are often substantial). The trial also ran for just 7 days, which tells us about a short-term response but nothing about whether the effect persists, fades, or requires ongoing use. And the sample size, while not published in the excerpt above, is consistent with a pilot study design — meant to generate a hypothesis for a larger trial, not settle the question.
What NAD+ won't do
This is not hormone replacement therapy, and it hasn't been tested against or alongside HRT. If hot flashes, night sweats, or other menopausal symptoms are significantly affecting your quality of life, a conversation with your doctor about the full range of options — including HRT, non-hormonal prescription options, and lifestyle approaches — is the appropriate next step. This pilot trial is a reason for cautious optimism about NAD+ precursors as a complementary option, not a reason to skip that conversation.
Frequently asked questions
Does NAD+ actually help with hot flashes?
A small 2026 open-label pilot trial found a 7-day course of NRPT significantly reduced hot flash frequency and severity. It's a genuinely promising early result, but it needs a larger, placebo-controlled trial to confirm.
Is this the same as hormone replacement therapy?
No. This works through a proposed cofactor mechanism supporting your body's own estrogen conversion, not through supplying external hormones. It hasn't been tested against or alongside HRT.
Why does an open-label trial matter less than a placebo-controlled one?
Without a placebo group, it's harder to separate a real biological effect from expectation effects — which are known to be substantial in hot-flash research specifically. The result is promising but needs replication in a blinded design.
How long would I need to take it to see an effect?
The pilot trial measured results after just 7 days, which is genuinely fast if real — but we don't yet know if benefits persist, grow, or require continued use over longer periods.
Estrogen and vascular health intersect in a few places we’ve covered — see NAD+ and libido for the related blood-flow mechanism, and the afternoon crash in perimenopause and menopause if fatigue during this transition is your main concern. Hair changes during menopause are also common; our article on NAD+ and gray hair fact-checks a related but separate claim.
Did the pilot trial test NMN as well as NRPT?
No — the 2026 pilot trial specifically tested NRPT (nicotinamide riboside plus pterostilbene). NMN hasn't been separately tested for menopausal hot flashes or symptoms in a published trial.
One design detail worth appreciating: the pilot trial’s comparator wasn’t a separate placebo group, but women without menopausal symptoms taking the same NRPT supplement — and that group did not show the same improvements in bloating, hot flashes, or sleep. That’s a meaningfully different (and somewhat more informative) comparison than nothing at all, since it suggests the effect tracked specifically with menopausal status rather than being a generic effect of taking any supplement. It’s still not equivalent to a randomized placebo arm within the same population, which is what a proper follow-up trial would need to include to rule out expectation effects definitively.
Given how recent this trial is — published in 2026 — it hasn’t yet had time to be independently replicated by another research group, which is typically how early pilot findings either get confirmed or fail to hold up. That’s not a criticism of the study itself, just an honest description of where any brand-new finding sits in the research pipeline: promising, published, and still waiting for confirmation.
From Nuvirox
Why we formulated NAD+ Restore
If what you're dealing with sounds like it belongs in a doctor's office rather than a supplement aisle, please start there — a clinician can rule out the specific causes discussed above. For general cellular energy support, each serving of NAD+ Restore provides 500 mg of nicotinamide riboside chloride (NR), one of the two most-researched NAD+ precursors, within the dose range used in published human trials, alongside 150 mg trans-resveratrol and 50 mg quercetin (polyphenols studied alongside NAD+ pathways for cellular health support) and 10 mg of galactomannans from fenugreek to support absorption.
We back it with a 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should.
Learn more about NAD+ Restore →The bottom line
This is one of the more interesting recent findings in NAD+ research — a plausible biological mechanism (NAD+ as a cofactor for estrogen conversion) paired with a real, if small and open-label, human trial showing symptom improvement in exactly the population you'd expect. The honest caveat is that open-label pilot trials are a first step, not a final answer, and hot flashes are notoriously responsive to placebo. Cautiously promising is the fair read here.
References
- Nicotinamide riboside and pterostilbene reduces frequency and severity of undesirable symptoms of the menopause transition: an open-label, pilot clinical trial. Front Aging. 2026. PMID: 42211736.
- Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. doi:10.1126/science.abe9985. PMID: 33888596.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.